Biotechnology

Moderna raises its full-year 2026 revenue growth guidance to between 15% and 25%, citing accelerating commercial traction across its newer vaccine portfolio.

Emerging ventures target reduced red meat consumption through hybrid proteins alongside breakthroughs in sight-restoring implants and autonomous web systems.